<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745043</url>
  </required_header>
  <id_info>
    <org_study_id>NTX/05/04/035</org_study_id>
    <nct_id>NCT00745043</nct_id>
  </id_info>
  <brief_title>Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study</brief_title>
  <acronym>BOLD</acronym>
  <official_title>Do Beta-Blockers Affect the Use of Beta-Agonist Inhalers in COPD?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Waikato Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Waikato Hospital Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Waikato Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These
      are very common conditions and many patients have both diseases. Beta-blocker drugs are
      extensively used in the treatment of angina, high blood pressure and after heart attacks to
      decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness
      and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in
      COPD patients as they may make the breathlessness worse, but it has now been established that
      they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the
      body and the investigators do not know if they can work together or if they would cancel each
      other out. The investigators also do not know which of the different types of beta-blockers
      now available are better for COPD patients. This study will investigate what happens to the
      airways of people taking both of these drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchodilator response to salbutamol after beta-blockers</measure>
    <time_frame>7-10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental Shuttle Walk Test Result after taking beta-blockers</measure>
    <time_frame>7-10 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>R302</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R303</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily metoprolol 95mg capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R304</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily propranolol 80mg capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily Metoprolol 190mg capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bronchodilator response</intervention_name>
    <arm_group_label>R302</arm_group_label>
    <arm_group_label>R303</arm_group_label>
    <arm_group_label>R304</arm_group_label>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of COPD

          -  &gt; 40 years of age

          -  &gt; 15 pack year smoking history

        Exclusion Criteria:

          -  Contra-indication to beta-blocker use

          -  Severe COPD FEV1 &lt; 30% or 1 L

          -  Not responsive the methacholine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bob Hancox, MD FRACP</last_name>
    <role>Study Director</role>
    <affiliation>Waikato Hospital Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Respiratory Medicine</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <last_update_submitted>August 29, 2008</last_update_submitted>
  <last_update_submitted_qc>August 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Catherina Chang Research Fellow</name_title>
    <organization>Respiratory Research Waikato Hospital</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Betablockers</keyword>
  <keyword>bronchodilator</keyword>
  <keyword>exercise capacity</keyword>
  <keyword>methacholine challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

